Anti-inflammatory combination having reduced ulcerogenicity

Details Anti-inflammatory combination having reduced ulcerogenicity Anti-inflammatory combination having reduced ulcerogenicity

1979-03-28

1980-10-14

Friedman, Stanley J.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

424274, A61K 31405, A61K 3162

Patent

active

042281610

ABSTRACT:
A novel drug combination for more effective treatment of pain, fever, and inflammation with reduced ulcerogenicity comprising (a) 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid (indomethacin), and (b) a member selected from phenyl benzoic acid compounds, especially 2-hydroxy-5-(2',4'-difluorophenyl)benzoic acid (diflunisal), wherein the molar ratio of (b) to (a) is from 0.5 to 1.0 to 15.0 to 1.0.

REFERENCES:
patent: 3161564 (1964-12-01), Morehouse
patent: 3674870 (1972-07-01), Ruyle
patent: 3714226 (1973-01-01), Ruyle
patent: 4016268 (1977-04-01), Goldenberg
patent: 4066756 (1978-01-01), Orr et al.
Hanchar et al., Gastroenterology, vol. 72, No. 5, Part 2 (1977).
Robert et al., Prostaglandins, vol. 14, No. 2, pp. 333-338 (1977).
Rainsford, Agents & Actions, vol. 7, 516, pp. 573-577 (1977).
Goburdhum et al., J. Pharma. Methods, vol. 1, pp. 109-114 (1978).
Pauls et al., Science, Jan. 2, 1948, pp. 19-20.
Scrip, Oct. 14, 1973, p. 24.

Affiliated with

Also associated with

Rating

Anti-inflammatory combination having reduced ulcerogenicity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-inflammatory combination having reduced ulcerogenicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory combination having reduced ulcerogenicity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2101042